

Prognostic Utility of Morning Blood Pressure Surge for 20-Year All-Cause and Cardiovascular Mortalities: Results of a Community-Based Study

Hao-Min Cheng, MD, PhD; Chung-Li Wu, MS; Shih-Hsien Sung, MD, PhD; Jia-Chun Lee, MS; Kazuomi Kario, MD, PhD; Chern-En Chiang, MD, PhD; Chi-Jung Huang, PhD; Pai-Feng Hsu, MD, PhD; Shao-Yuan Chuang, PhD; Edward G. Lakatta, MD; Frank C. P. Yin, MD, PhD; Pesus Chou, PhD; Chen-Huan Chen, MD

Background—Morning blood pressure (BP) surge (MS), defined by the MS amplitude, is an independent prognostic factor of cardiovascular outcomes in some, but not all, populations.

Method and Results—We enrolled 2020 participants (1029 men; aged 30–79 years) with 24-hour ambulatory BP data. During a median 19.7-year follow-up, 607 deaths (182 by cardiovascular causes) were confirmed from the National Death Registry. The amplitude of sleep-trough MS (STMS) was derived from the difference between morning systolic BP (SBP) and lowest nighttime SBP. The rate of STMS was derived as the slope of linear regression of sequential SBP measures on time intervals within the STMS period. Thresholds for high STMS amplitude and rate were determined by the 95th percentiles (43.7 mm Hg and 11.3 mm Hg/h, respectively). Multivariable Cox models, adjusting for age, sex, body mass index, smoking, alcohol, low-density lipoprotein cholesterol, 24-hour SBP, night:day SBP ratio, and antihypertensive treatment, revealed that a high STMS rate (hazard ratio, 1.666; 95% confidence interval, 1.185–2.341), but not STMS amplitude (hazard ratio, 1.245; 95% confidence interval, 0.984–1.843), was significantly associated with a greater mortality risk. Similarly, STMS rate (hazard ratio, 2.608; 95% confidence interval, 1.554–4.375), but not STMS amplitude, was significantly associated with the risk of cardiovascular mortality (hazard ratio, 0.966; 95% confidence interval, 0.535–1.747). Moreover, the prognostic values of STMS rate were comparable in subjects with or without morning and nocturnal hypertension (*P*>0.05 for interaction for all). In simulation studies, STMS rate was less susceptible to measurement errors of the sleep-trough SBP than STMS amplitude.

Conclusions—STMS rate could independently help identify subjects with an increased cardiovascular risk. (*J Am Heart Assoc.* 2017;6:e007667. DOI: 10.1161/JAHA.117.007667.)

Key Words: ambulatory blood pressure monitoring • blood pressure • cardiovascular mortality • cardiovascular outcomes • morning blood pressure surge

B lood pressure (BP) values vary markedly from day to night and from night to day; a nocturnal BP decrease is followed by a morning BP increase. Alterations in the short-term (within 24 hours) circadian physiological BP variation may have an independent prognostic value and may be

relevant for clinical detection and intervention.¹ A large BP increase in the early morning has coincided with the fact that morning is a vulnerable period during which more cardiovascular events occur than at later times in the day.² Ambulatory BP monitoring (ABPM), by tracking changes in the BP level

From the Department of Medicine (H.-M.C., S.-H.S., P.-F.H., P.C., C.-H.C.), Department of Medical Education, Center for Evidence-Based Medicine (H.-M.C., C.-L.W., J.-C.L., C.-J.H., C.-H.C.), and General Clinical Research Center (C.-E.C.), Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health (H.-M.C., S.-H.S., P.-F.H., C.-H.C.) and Faculty of Medicine (H.-M.C., S.-H.S., P.-F.H., C.-H.C.), National Yang-Ming University, Taipei, Taiwan; National Health Research Institutes, Miaoli, Taiwan (S.-Y.C.); Laboratory of Cardiovascular Science in the National Institute on Aging Intramural Research Program, Baltimore, MD (E.G.L.); Department of Biomedical Engineering, Washington University, St Louis, MO (F.C.P.Y.); and Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.).

Accompanying Data S1, Tables S1 through S7, and Figure S1 are available at http://jaha.ahajournals.org/content/6/12/e007667/DC1/embed/inline-suppleme ntary-material-1.pdf

Correspondence to: Hao-Min Cheng, MD, PhD, or Chen-Huan Chen, MD, Center for Evidence-Based Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei, Taiwan. E-mails: hmcheng@vghtpe.gov.tw or chench@vghtpe.gov.tw

Received October 12, 2017; accepted October 25, 2017.

© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Clinical Perspective

What Is New?

- Conventional sleep-trough morning blood pressure (BP) surge (STMS) focused only on the amplitude rather than the rate of BP increase.
- We calculated the STMS rate as the slope of linear regression of sequential systolic BP measures on time intervals within the STMS period.
- The reproducibility of the STMS rate was better than that of the STMS amplitude. The STMS rate was also a more sensitive and reliable prognostic factor for long-term mortality than the STMS amplitude.
- The prognostic values of the STMS rate were comparable in subjects with or without morning and nocturnal hypertension

What Are the Clinical Implications?

 Because the STMS rate can be easily calculated from the ambulatory BP monitoring data, it has the potential to become a routine parameter in daily practice for subjects receiving ambulatory BP monitoring, in conjunction with other routinely derived parameters, including STMS amplitude.

over 24 hours, provides the opportunity to test the hypothesis that the high incidence of cardiovascular complications in the morning is linked to an exaggerated night-to-day BP elevation.³ Indeed, the morning BP surge (MS) has been demonstrated to be an important prognostic factor of cardiovascular end points in Japanese elderly hypertensive patients⁴ and in many other population-based cohorts.^{5,6} In a meta-analysis of 5645 subjects from 8 cohorts, sleep-trough MS (STMS) significantly and independently associated with cardiovascular outcomes.⁵ However, the prognostic value of MS for cardiovascular disease was not confirmed by recent prospective studies.^{7–9}

The inconsistent results on the clinical significance of MS may indicate the need to investigate the different aspects of MS. Previous studies, however, only assessed the prognostic value of the STMS magnitude and the level of achieved morning BP, and they neglected the contribution of the rate at which morning BP increases to incur risk. To fully characterize the influence of STMS on the early morning risk of cardio-vascular events, it is warranted to consider not only the amplitude but also the rate of STMS. We hypothesized that the rate of a BP increase carries valuable prognostic information in association with cardiovascular outcomes beyond the amplitude of STMS. Moreover, subjects with morning and nocturnal hypertension are known to have increased risks for cardiovascular events and total mortality. Whether the presence of morning or nocturnal

hypertension could modify the prognostic value of MS is largely unknown. ¹⁰ Therefore, the present study aimed to investigate the independent prognostic significance of MS parameters in predicting long-term all-cause and cardiovascular mortalities in a community-based cohort.

Moreover, considering that frequent BP measurements during sleep may disturb sleep and reduce nocturnal BP decrease, and less frequent BP measurements may not capture the true sleep-trough BP, we therefore conducted a series of simulation studies of possible scenarios to investigate the influences of measurement errors on the rate and amplitude of STMS.

Methods

Study Population

The data that support the findings of this study are available from the corresponding author on reasonable request. The study population consisted of 2020 participants (overall, 1029 men; aged 30-79 years) with complete demographic and 24hour ABPM data drawn from a community-based survey conducted from Sep 3, 1991 to June 16, 1993. 12 Subjects having taken antihypertensive agents were also included. As such, the sample size of the present study was larger than that in our previous study. 13 Only subjects without nighttime BP data were excluded, and the all-inclusive manner allowed all unedited ambulatory BP data for analysis, which resembles clinical practice. All participants received a baseline comprehensive cardiovascular evaluation, including complete medical history, physical examination, and blood chemistry analysis from overnight fasting serum and plasma samples. 13,14 None of the participants had a previous history of diabetes mellitus, angina pectoris, or peripheral vascular disease, and none had clinical or echocardiographic evidence of other significant cardiac diseases. The study was approved by Taipei Veterans General Hospital (Taipei, Taiwan) and the institutional review board at Johns Hopkins University (Baltimore, MD), with the exemption of informed consent.

Twenty-Four-Hour Ambulatory BPs and MS

The office BP measurements were taken in a special clinic established at the local health station for 3 to 5 months to examine the eligible subjects in the selected 3 regions in Taiwan. Office systolic BP (SBP) and diastolic BP (DBP) levels were measured manually by experienced cardiologists using a mercury sphygmomanometer. Two or more measurements separated by at least 5 minutes were taken from the right arm of participants after they had been seated for at least 5 minutes. The average of at least 2 consecutive measurements was then recorded and used for analysis.

3

Descriptions of the conduct of the field study and ABPM measurements have been detailed elsewhere. 12,14 In brief, after instructions, all study subjects received the examination of 24-hour ABPM on a usual working day. The recorder (model 90217; Spacelabs Inc, Redmond, WA) was programmed to measure ambulatory BP (full inflation, followed by deflation, in steps of 8 mm Hg) at 20-minute intervals during the daytime (ie, from 6 AM to 10 PM) and at 60-minute intervals during the nighttime (ie, from 10 PM to 6 AM). The morning period was defined as the interval in the first 2 hours of the daytime, the evening period was defined as the last 2 hours before nighttime, and a preawakening period was defined as the last 2 hours of the nighttime. Sleep-trough SBP was defined as the lowest nighttime reading. MS can, therefore, be described as follows (Figure 1): (1) STMS, defined as the morning SBP (average of the SBP readings during the morning period) minus the sleep-trough SBP; (2) preawakening surge, defined as the morning SBP minus the preawakening SBP (average of the SBP readings during the preawakening period); (3) morning-evening SBP difference, defined as the difference between morning and evening SBP (average of the SBP readings during the evening period); and (4) morning-night SBP difference, defined as the difference between morning and nighttime SBP (average of the SBP readings during the

nighttime). SBP night:day ratio was calculated as the ratio of nighttime SBP:daytime SBP (average of the SBP readings during the daytime). For each individual subject, the rate of STMS was derived as the slope of the linear regression of successive SBP measures on time intervals within the time frame of STMS. Morning hypertension was defined as BP of at least 135/85 mm Hg for ambulatory readings within the first 2 hours of daytime. 10 Nocturnal hypertension was defined by nighttime SBP \geq 120 mm Hg or DBP \geq 70 mm Hg. 15

To avoid interobserver and intraobserver variations, we performed a fully automated batch analysis for the calculation of 24-hour BP readings from ABPM using a custom-designed routine in Matlab, versions 4.2 and 7.0 (The MathWorks, Inc).

Reproducibility

We conducted the reproducibility analysis on the basis of a Japanese reproducibility study 16 for MS parameters.

Follow-Up

We ascertained the causes and dates of death for all participants deceased before December 31, 2013, by linking our database with the National Death Registry through a




Figure 1. Illustration of parameters describing the sleep-trough morning blood pressure surge (STMS). After identification of nighttime blood pressure (BP) trough and morning BP peak, linear regression analysis between BP (*y* axis) and time (*x* axis) was conducted. The slope of the BP increase is the STMS rate.

unique personal identification number given to every Taiwanese citizen. The National Death Registry holds valid information based on the certified death certificates, coded according to the *International Classification of Disease, Ninth and Tenth Revisions (ICD-9* and *ICD-10*, respectively). The *ICD-9* and *ICD-10* codes representing cardiovascular deaths were 390 to 459 and I00 to I99, respectively. The accuracy of cause-of-death coding in Taiwan's National Death Registry database has been validated.¹⁷

Statistical Analysis

All data are expressed as proportions (percentages) or means and SDs. Associations of the STMS rate and amplitude with all-cause and cardiovascular mortalities over a median followup of 20 years were examined by the Cox proportional hazard regression analysis. We first evaluated the hazard ratios (HRs) of these parameters in quintiles and >95th percentile for allcause and cardiovascular mortalities. The baseline multivariable Cox model was constructed on the basis of significant results from the univariate analyses for sex, age, height, alcohol, dyslipidemia, smoking, hypertension, total cholesterol, low- and high-density lipoprotein cholesterol, triglycerides, heart rate, office SBP, 24-hour SBP, 24-hour DBP, daytime SBP, nighttime SBP, morning SBP, and a previous systematic review.⁵ We determined the threshold for high status of the morning surge parameters by identifying the 95th percentile. To investigate the relationship between MS and long-term all-cause and cardiovascular mortalities in different conditions, we conducted a series of sensitivity analyses. A 2-tailed P<0.05 was considered statistically significant. The analyses were performed using SAS, version 9.3, and the software package Comprehensive Meta-Analysis, version 2 (Bio Stat, Englewood, NJ). 18

Simulation Studies

A higher sampling rate at night may help capture a lower sleep-trough SBP but may also interfere with subjects' sleep quality and the extent of nocturnal BP decrease. We, therefore, conducted a series of simulation studies (Data S1) described as follows to investigate the effect of measurement errors of true sleep-trough SBP on the STMS rate and amplitude and the corresponding regression dilution analysis.

In brief, in simulation study 1 (N=2020; present cohort), we simulated the true sleep-trough SBP as if the true lowest sleep SBP was before or after the originally identified one (Figure S1); in simulation study 2 (N=42; Japanese reproducibility study), we conducted the simulation by reducing the nighttime sampling frequency of ABPM on the basis of a previously published study population. ¹⁶ In addition, the calculation of morning SBP may also be affected by the

awakening time. Therefore, in simulation study 3 (N=2020; present cohort), we simulated the true awakening time before or after the original setting.

Results

Characteristics of the study population are shown in Table 1. Compared with subjects with normal STMS rates, those with high rates had greater body weight, body mass index, total and low-density lipoprotein cholesterol levels, 24-hour SBP and DBP, and morning SBP. Office SBP and DBP were comparable.

During a median 19.7-year follow-up, there were 607 deaths (182 with cardiovascular causes). Univariate analysis of predictors of cardiovascular and all-cause mortalities in the continuous scale are shown in Table S1. Among the MS parameters of STMS, preawakening surge, morning-evening SBP difference, and morning-night SBP difference were significantly associated with all-cause mortality, and only rate of STMS and morning-night SBP difference were significantly associated with cardiovascular mortality. In multivariable analysis adjusting for age, sex, antihypertensive treatment, body mass index, low-density lipoprotein cholesterol, smoking, alcohol drinking, 24-hour SBP, and the SBP night:day ratio, only rate of STMS was significantly associated with all-cause mortality (Table S2).

The relationships between mortality risk and STMS amplitude or rate in quintiles and above the 95th percentile (threshold for high status) were evaluated by multivariable Cox models and are shown in Figures 2 and 3, respectively. Subjects with STMS amplitude ≥43.7 mm Hg (95th percentile; Figure 2) did not show a significant increase in allcause or cardiovascular mortalities compared with subjects with a normal STMS amplitude (all-cause mortality: HR, 1.245; 95% confidence interval, 0.911-1.701; *P*=0.1691; cardiovascular mortality: HR, 0.966; 95% confidence interval, 0.535-1.747; P=0.9101; Table 2). In contrast, subjects with an STMS rate ≥11.3 mm Hg/h (95th percentile; Figure 3) had a significantly increased risk of all-cause and cardiovascular mortalities compared with subjects with an STMS rate <11.3 mm Hg/h (all-cause mortality: HR, 1.666; 95% confidence interval, 1.185-2.341; P=0.0033; cardiovascular mortality: HR, 2.608; 95% confidence interval, 1.554-4.375; P=0.0003; Table 2). A categorical analysis, which classified subjects into high and normal MS using thresholds for defining abnormally high MS parameters at the 95th percentile (Table 2), a high MS defined by the rate of STMS was significantly associated with total and cardiovascular mortalities. Similar trends were observed when the cut point of 90th percentile was used (Table S3). The sensitivity analysis demonstrated consistent results by including only records with 80% successful measurements for the analysis

Table 1. Baseline Characteristics of the Study Population and Subjects With Normal or High Rate of MS Based on the Cutoff of 11.33 mm Hg/h

| | Total Population | Normal Rate of STMS | High Rate of STMS | |
|------------------------------------|------------------|---------------------|-------------------|---------|
| Characteristics | (N=2020) | (n=1919) | (n=101) | P Value |
| Sex (male) | 1029 (51.4) | 973 (51.2) | 56 (55.4) | 0.4127 |
| Age, y | 55.2±13.1 | 55.2±13.2 | 55.1±12.1 | 0.9083 |
| Height, cm | 158.8±8.5 | 158.8±8.5 | 159.5±9.1 | 0.4368 |
| Weight, kg | 63.1±11.1 | 63.0±11.1 | 65.7±10.9 | 0.0191 |
| Body mass index, kg/m ² | 25.0±3.7 | 24.9±3.7 | 25.8±3.7 | 0.0230 |
| Alcohol | 243 (12.1) | 226 (11.9) | 17 (16.8) | 0.1400 |
| Dyslipidemia | 325 (17.9) | 296 (17.2) | 29 (30.8) | 0.0008 |
| Smoking | 511 (25.5) | 479 (25.2) | 32 (31.6) | 0.1479 |
| Hypertension | 861 (42.6) | 824 (42.9) | 37 (36.6) | 0.2117 |
| Antihypertensive agents | 861 (42.6) | 824 (42.9) | 37 (36.6) | 0.2117 |
| Total cholesterol, mg/dL | 200.8±38.9 | 200.0±38.3 | 215.6±45.6 | 0.0015 |
| LDL-C, mg/dL | 124.6±34.9 | 124.1±34.5 | 133.6±41.6 | 0.0341 |
| HDL-C, mg/dL | 49.5±13.0 | 49.5±13.0 | 49.8±12.6 | 0.8079 |
| Triglycerides | 138.9±115.6 | 137.3±112.8 | 168.5±158.2 | 0.0613 |
| Heart rate, beats/min | 70.5±13.7 | 70.6±13.9 | 69.7±9.9 | 0.3921 |
| Office SBP, mm Hg | 142.7±25.1 | 142.5±25.0 | 147.7±26.1 | 0.0429 |
| Office DBP, mm Hg | 89.4±23.4 | 89.3±23.8 | 91.7±14.9 | 0.1415 |
| 24-h SBP | 128.5±17.5 | 128.4±17.4 | 133.0±19.1 | 0.0090 |
| 24-h DBP | 81.3±11.7 | 81.2±11.6 | 84.4±12.3 | 0.0073 |
| Daytime SBP, mm Hg | 130.3±17.7 | 130.0±17.6 | 136.1±20.2 | 0.0035 |
| Nighttime SBP, mm Hg | 122.3±18.2 | 122.4±18.3 | 121.7±17.0 | 0.6908 |
| Morning SBP, mm Hg | 130.4±19.3 | 129.9±19.1 | 140.0±19.2 | <0.0001 |
| Amplitude of STMS, mm Hg | 21.7±12.3 | 21.0±12.0 | 35.0±11.7 | <0.0001 |
| Rate of STMS, mm Hg/h | 3.3±4.1 | 2.7±3.1 | 14.7±3.5 | <0.0001 |
| Preawakening surge, mm Hg | 8.6±14.5 | 7.4±13.6 | 31.8±10.8 | <0.0001 |
| ME difference, mm Hg | 1.8±13.5 | 1.7±13.6 | 3.4±12.0 | 0.2323 |
| MN difference, mm Hg | 7.9±10.6 | 7.4±10.4 | 17.9±9.7 | <0.0001 |
| Trough SBP, mm Hg | 106.6±17.3 | 106.9±17.4 | 101.0±15.4 | 0.001 |

Data are given as number (percentage) or mean ±SD. DBP indicates diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ME difference, difference between morning and evening SBP; MN difference, difference between morning and night SBP; MS, morning blood pressure surge; SBP, systolic blood pressure; and STMS, sleep-trough MS.

and at least 8 BP measurements within the time frame from sleep-trough through to the morning period (Table S4) and by stratifying patients on the basis of subjects receiving antihypertensive agents or not (Table S5).

Survival curves stratified according to high or normal STMS amplitude and rate are presented in Figure 4A and 4B. We then stratified subjects into subgroups with or without morning hypertension or nocturnal hypertension. As shown in Figure 5, in multivariable Cox proportional hazard models accounting for sex, age, antihypertensive treatment, body mass index, low-density lipoprotein cholesterol, smoking, alcohol drinking, and 24-hour SBP, the prognostic values of a high STMS rate in these subgroups were comparable with all P>0.05 for interaction, suggesting its independent prognostic role in these subgroups.

The 3 simulation studies compared the relative sensitivity of STMS rate and amplitude with measurement errors of true sleep-trough SBP, reduced nighttime sampling rate, and deviation from the true awakening time. In all simulation studies, the standardized mean differences between the




Figure 2. Multivariable model of the associations of amplitude of sleep-trough morning blood pressure (BP) surge with all-cause mortality (A) and cardiovascular mortality (B), with adjustment for sex, age, antihypertensive treatment, body mass index, low-density lipoprotein cholesterol, smoking, alcohol drinking, 24-hour systolic BP, and systolic BP night:day ratio. Quintile 1 (Q1) was the reference. 95th indicates 95th percentile; and CI, confidence interval.

simulated values and original measured values were consistently lower for the STMS rate than for the STMS amplitude (Table S6).

Results of the reproducibility study are shown in Table S7. The intraclass coefficients between 2 repeated measurements for the same individual were 0.31 and 0.21 for the STMS rate and amplitude, respectively.

Discussion

Although a large and rapid BP increase in the early morning has been associated with a poor prognosis, previous

studies focused only on the amplitude rather than the rate of BP increase. BP is normally low at night while sleeping and starts to increase a few hours before waking up, exhibiting a physiological diurnal variation. Only an extreme morning BP increase is considered hazardous to the cardiovascular system. However, only the STMS rate was significantly associated with mortalities of our study subjects. Therefore, the STMS rate appears to be a more sensitive prognostic factor than the STMS amplitude, derived from the 24-hour ABPM data in association with cardiovascular outcomes. These findings could also be supported by the largest statistical power of STMS




Figure 3. Multivariable model of the associations of the rate of sleep-trough morning blood pressure (BP) surge with all-cause mortality (A) and cardiovascular mortality (B), with adjustment for sex, age, antihypertensive treatment, body mass index, low-density lipoprotein cholesterol, smoking, alcohol drinking, 24-hour systolic BP, and systolic BP night:day ratio. Quintile 1 (Q1) was the reference. 95th indicates 95th percentile; and CI, confidence interval.

Table 2. Multivariable Analysis for the Prognostic Values of Various Parameters Describing Night-to-Morning SBP Changes With All-Cause and Cardiovascular Mortality

| | | | | | All-Cause Mortality (Event=607) | | | | Cardiovascular Mortality (Event=182) | | | |
|---------------------------|-------------|-------|-------------|---------|--|-------|--------------|---------|---|--|--|--|
| Parameters | Thresholds* | HR | 95% CI | P Value | Statistical Power for All-Cause Death [†] | HR | 95% CI | P Value | Statistical Power for Cardiovascular Death [†] | | | |
| Amplitude of STMS, mm Hg | 43.67 | 1.245 | 0.911–1.701 | 0.16 | 0.25 | 0.966 | 0.535-1.747 | 0.9101 | 0.05 | | | |
| Rate of STMS, mm Hg/h | 11.33 | 1.666 | 1.185–2.341 | 0.0033‡ | 0.84 [‡] | 2.608 | 1.554-4.375 | 0.0003‡ | 0.86 [‡] | | | |
| Preawakening surge, mm Hg | 32.75 | 0.826 | 0.534–1.277 | 0.39 | 0.2 | 1.380 | 0.3048-2.555 | 0.3048 | 0.18 | | | |
| ME difference, mm Hg | 25.73 | 1.24 | 0.916–1.679 | 0.16 | 0.24 | 1.183 | 0.664–2.108 | 0.5692 | 0.08 | | | |
| MN difference, mm Hg | 25.7 | 1.114 | 0.767-1.620 | 0.57 | 0.1 | 0.728 | 0.343-1.545 | 0.4086 | 0.17 | | | |

Each morning blood pressure surge parameter was 1-by-1 tested in a multivariable Cox proportional hazard model. Models were adjusted for sex, age, antihypertensive treatment, body mass index, low-density lipoprotein cholesterol, smoking, alcohol drinking, 24-hour SBP, and the SBP night:day ratio. Cl indicates confidence interval; HR, hazard ratio; ME difference, difference between morning and evening SBP; MN difference, difference between morning and night SBP; SBP, systolic blood pressure; and STMS, sleep-trough morning blood pressure

rate than all other MS parameters, as demonstrated in Table 2.

A previous meta-analysis based on individual participant data demonstrated that individuals with isolated nocturnal hypertension were associated with a significantly higher risk of total mortality and all cardiovascular events than normotensive individuals. 11 In comparison with MS parameters, morning hypertension may be an easier target to manage because both ABPM and home BP monitoring can provide morning BP measurements.²⁰ However, both a high nocturnal BP and an exaggerated MS can contribute to morning hypertension. More important, as shown in Figure 5, the prognostic values in subject with or without morning or nocturnal hypertension were comparable. This important finding may suggest the indispensable role of ABPM in measuring nocturnal BP and MS parameters and clearly supports the important prognostic utility of MS parameters.

A higher nighttime sampling rate could have captured a lower sleep-trough SBP and a larger STMS as a result, but could also be offset by a poorer sleep quality and an incomplete nocturnal BP decrease. Therefore, the simulation studies may be valuable in quantifying the impact of such technical constraints of cuff-based BP measurement. In our simulation studies, we evaluated the impact of the measurement errors resulting from the identification of sleep-trough SBP, a lower sampling rate, and inaccurate preawakening time on the estimated STMS amplitude and rate. We clearly demonstrated that the STMS rate was less susceptible to the measurement errors than the STMS amplitude. Moreover, the observed HRs for mortality with STMS rate or amplitude could have been underestimated because of the effect of regression dilution resulting from the measurement error. Therefore, the STMS rate may be a more reliable estimate to describe the adverse effect of the MS. These findings are imperative to clinical practice, which may help to explain the previous inconsistent prognostic values of STMS.6

In a previous meta-analysis of subjects from 8 populations,⁵ STMS amplitude >90th percentile was an independent risk factor of mortality and cardiovascular events after adjusting for the same covariables as in our study. Given the relatively small sample size and fewer end points in our study (607 all-cause deaths), the STMS amplitude only reached borderline prognostic significance, whereas all other MS parameters were of no significant prognostic value. In contrast, STMS rate was significantly associated with both cardiovascular and total mortalities in our community-based

Morning BP increase is a well-recognized physiological phenomenon, 2,21,22 but few studies have investigated the prognostic value of the rate of BP increase. Staessen et al reported, in 1999, that a higher sleeping-to-waking morning BP increase rate (slope), indirectly calculated by fitting a regression line from 4 to 10 AM, was associated with a lower risk of cardiovascular events.²³ In contrast to the fixed interval method adopted by Staessen et al,23 the rate of STMS in the present analysis was calculated by first identifying the nighttime SBP trough and then fitting a regression over the trough-to-morning period. In addition, only subjects with STMS rates >95th percentile had a significantly increased risk of mortality, which suggests that only an extreme condition of a well-recognized physiological phenomenon can be associated with a harmful effect.

^{*}The thresholds were determined by the 95th percentile of parameters describing the night-to-morning SBP change.

[†]For both all-cause and cardiovascular deaths, a significant increase of risk for normal vs high STMS rate is practically meaningful. There is 84% power to detect a 66% increase of risk for all-cause death, given a sample size of 2020 patients, a hazard ratio of 1.666, an overall probability of death of 0.3475, a ratio of patients in the group of high STMS rate as 5%, and a type I error rate of 5%. Similarly, for the power for cardiovascular death, with the previously described conditions, except for hazard ratio of 2.608, the overall probability of cardiovascular death is 0.1042 and there is 86% power to detect a 160% increase of risk.

^{\$}Given the present sample size, the explanation of the p values and statistical power for all-cause and cardiovascular mortalities were illustrated as above.




Figure 4. Survival curves of subjects stratified according to high or normal amplitude of sleep-trough morning blood pressure surge (STMS; A) and high or normal rate of STMS (B). CI indicates confidence interval; and HR, hazard ratio.

The amplitude of STMS in the present study had only borderline prognostic significance for mortalities, which may be explained by several reasons. First, compared with the previous seminal study investigating the prognostic value of STMS in elderly hypertensive outpatients, our population-based study subjects were relatively younger, with a lower

mean 24-hour SBP level.⁴ The characteristics of our study population may dilute the impact of the amplitude of STMS on cardiovascular mortality, which may be modulated by age and 24-hour SBP level. Second, with the long follow-up period, confounding factors, such as the initiation of antihypertensive therapy, may reduce the risk of baseline MS, especially in the




Figure 5. The prognostic values of high vs normal rate of sleep-trough morning blood pressure surge (STMS rate) in subgroups with or without morning hypertension (defined by morning systolic blood pressure >135 mm Hg or diastolic blood pressure >85 mm Hg)¹⁰ and with or without nocturnal hypertension (defined by nighttime systolic blood pressure >120 mm Hg or diastolic blood pressure >70 mm Hg).¹⁵

younger patients. Third, the issue of measurement errors, especially during nighttime, which has been comprehensively investigated in our study, might also result in the regression dilution effect. However, even with the previously described confounding factors, which may reduce the true impact of MS and STMS amplitude, the rate of STMS could still significantly associate with all-cause and cardiovascular mortalities. Further studies should be conducted to evaluate whether the STMS rate in different age populations confers differential impacts and has comparable manageability in response to medications.²⁴

Although BP measurement every 15 to 30 minutes during asleep hours for ABPM was formally recommended in 2005, 25 the adequacy has never been scientifically proved. In our simulation studies, we have demonstrated clearly that rate of STMS is less susceptible to measurement error than the amplitude by involving more BP measurements within the time frame between the nighttime trough and morning. Compared with the measurement of the amplitude of MS, the calculation of the rate of STMS involves many more BP measurements; however, it is a trade-off decision between the frequency of nighttime BP measurement and sleep quality. In addition, the STMS rate was less susceptible to errors than STMS amplitude when a fixed circadian window was used, as shown in simulation study 3.

Because the STMS rate can be easily calculated from the ambulatory BP data, it could become a routine parameter in daily practice for subjects receiving ABPM in conjunction with other routinely derived parameters, including STMS amplitude. Further clinical application is anticipated if similar results are found in other cohorts. In our reproducibility analysis on a Japanese population (Table S7), the reproducibility for the STMS rate was better than the reproducibility for the STMS amplitude. Future novel technology, such as cuff-less BP monitoring, which can substantially reduce the interference resulting from the cuff inflation and deflation of oscillometric BP measurements, may have potential in increasing the reproducibility of the MS parameters and more accurately determining the STMS amplitude and rate.

Limitations

Nonfatal cardiovascular events were not considered in the present study. Therefore, the prognostic value of MS parameters for all cardiovascular events may have been underestimated. The definitions of daytime and nighttime were arbitrarily determined by the research team 25 years ago. We, therefore, conducted simulation study 1 to account for such an inaccuracy. History of drug therapy during the follow-up period was not available. Thus, we only accounted for the impact of baseline antihypertensive medications on the prognostic values in the multivariable models, as done in a previous

meta-analysis.⁵ The use of antihypertensive treatment as a time-dependent variable is infeasible because the field study was conducted long before the commencement of the national health insurance program, and there were no relevant records for analysis. We did, however, analyze the possible modulating effect of antihypertensive agents on the relationship between MS and cardiovascular and all-cause mortalities. As shown in the stratified analysis based on taking or not taking antihypertensive agents in Table S5, all P values for interaction were insignificant, suggesting that antihypertensive agents had trivial influence on the prognostic role of MS. In fact, given that the use of antihypertensive agents could probably ameliorate the association between STMS and cardiovascular outcomes, the original prognostic value of STMS rate may be even more pronounced, considering the possibility of regression dilution, if there is any. The information of sleep apnea syndrome was not obtainable 25 years ago. However, sleep apnea syndrome is associated with an increased cardiovascular risk and linked with elevated nocturnal BP. On the basis of the equation for calculating STMS amplitude, the elevated nocturnal BP is related to a lower STMS amplitude. Therefore, sleep apnea could be a significant confounder that might dilute the prognostic value of MS. Even with the possible diluting effects of sleep apnea syndrome, our study still demonstrated the independent prognostic value of MS for 20-year all-cause and cardiovascular mortalities. As shown in Figure 5, exaggerated MS had a comparable prognostic value in subjects with or without morning or nocturnal hypertension. The results suggest the independent role of both morning or nocturnal hypertension and STMS, which may have significant clinical implication for the care of hypertensive patients.

Sources of Funding

This work was supported in part by grants from the National Science Council (NSC 99-2314-B-010-034-MY3, MOST 103-2314-B-010-050-MY2, and MOST 106-2314-B-075-051-MY3), an intramural grant from the Taipei Veterans General Hospital (grant V104C-140), Research and Development contract NO1-AG-1-2118, grants from the Ministry of Health and Welfare (MOHW104-TDU-B-211-113-003, MOHW106-TDU-B-211-113001), and the Intramural Research Program of the National Institute on Aging, National Institutes of Health.

Disclosures

None.


References

 O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K,

- Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens*. 2013;31:1731–1768.
- Argentino C, Toni D, Rasura M, Violi F, Sacchetti ML, Allegretta A, Balsano F, Fieschi C. Circadian variation in the frequency of ischemic stroke. Stroke. 1990;21:387–389.
- Schettini C, Bianchi M, Nieto F, Sandoya E, Senra H; Hypertension Working Group. Ambulatory blood pressure: normality and comparison with other measurements. *Hypertension*. 1999;34:818–825.
- Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation*. 2003;107:1401–1406.
- Li Y, Thijs L, Hansen TW, Kikuya M, Boggia J, Richart T, Metoki H, Ohkubo T, Torp-Pedersen C, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Sandoya E, Kawecka-Jaszcz K, Ibsen H, Imai Y, Wang J, Staessen JA; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010;55:1040–1048.
- Sheppard JP, Hodgkinson J, Riley R, Martin U, Bayliss S, McManus RJ. Prognostic significance of the morning blood pressure surge in clinical practice: a systematic review. Am J Hypertens. 2015;28:30–41.
- Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. *Hypertension*. 2006;47:149–154.
- 8. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, Ambrosio G, Reboldi G. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. *Hypertension*. 2012;60:34–42.
- Israel S, Israel A, Ben-Dov IZ, Bursztyn M. The morning blood pressure surge and all-cause mortality in patients referred for ambulatory blood pressure monitoring. Am J Hypertens. 2011;24:796–801.
- Wang JG, Kario K, Park JB, Chen CH. Morning blood pressure monitoring in the management of hypertension. J Hypertens. 2017;35:1554–1563.
- 11. Fan H-Q, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036–2045.
- Chen CH, Ting CT, Lin SJ, Hsu TL, Chou P, Kuo HS, Wang SP, Yin FC, Chang MS. Relation between diurnal variation of blood pressure and left ventricular mass in a Chinese population. *Am J Cardiol*. 1995;75:1239–1243.

- Sung SH, Cheng HM, Wang KL, Yu WC, Chuang SY, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. White coat hypertension is more risky than prehypertension: important role of arterial wave reflections. *Hypertension*. 2013;61:1346– 1353
- Chen CH, Ting CT, Lin SJ, Hsu TL, Ho SJ, Chou P, Chang MS, O'Connor F, Spurgeon H, Lakatta E, Yin FC. Which arterial and cardiac parameters best predict left ventricular mass? *Circulation*. 1998;98:422–428.
- 15. Kikuya M, Hansen TW, Thijs L, Bjorklund-Bodegard K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation. 2007;115:2145–2152.
- Eguchi K, Hoshide S, Hoshide Y, Ishikawa S, Shimada K, Kario K. Reproducibility of ambulatory blood pressure in treated and untreated hypertensive patients. J Hypertens. 2010;28:918–924.
- Lu TH, Lee MC, Chou MC. Accuracy of cause-of-death coding in Taiwan: types
 of miscoding and effects on mortality statistics. *Int J Epidemiol*. 2000;29:336

 343.
- Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 2. Englewood, NJ: Biostat; 2005.
- Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. *Hypertension*. 2010;56:765–773.
- Kario K. Time for focus on morning hypertension: pitfall of current antihypertensive medication. Am J Hypertens. 2005;18:149–151.
- Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am J Cardiol. 2002;89:27a–33a.
- 22. Kaplan NM. Morning surge in blood pressure. Circulation. 2003;107:1347.
- Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J; Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539–546.
- Kario K. Is vascular morning blood pressure surge in the elderly resistant to antihypertensives and more risky? *Hypertension*. 2012;60:e16; author reply e17–e18.
- 25. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals, part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.
- Gao M, Cheng HM, Sung SH, Chen CH, Olivier NB, Mukkamala R. Estimation of pulse transit time as a function of blood pressure using a nonlinear arterial tube-load model. *IEEE Trans Biomed Eng.* 2017;64:1524– 1534



Data S1.

Simulation studies

The construction of the simulation study 1 for the ambulatory data of the present study population (N =2020) are provided in Figure S1. We set up 6 simulated scenarios by generating three different values of sleep-trough SBP (observed sleep-trough SBP minus 5, 10 and 15 mm Hg) as the assumingly skipped true lowest nighttime SBP that would have occurred within 30 minutes before or after the actual recording time. Subsequently, we randomly selected the 6 scenarios for 1000 times and calculated the corresponding standardized mean differences (SMD) for STMS rate and amplitude between the simulated "true" and values calculated from the original ABPM recordings. Risk estimates could be diluted by measurement errors, a term named regression dilution.²

To further clarify the measurement errors resulting from the lower nighttime sampling rate, we carried out simulation study 2 for the ambulatory BP data obtained from a previously published study. In the study published by Kario K et al., the nighttime sampling rate of the ambulatory BP was twice an hour. We simulated the condition of a lower sampling rate (one measurement per hour) by selecting one BP measurement at one-hour interval over nighttime period. In addition, we also conducted a simulation study 3 by the assumingly true awakening time at 5:00 am or 6:30 am. Subsequently, we investigated the influence of these measurement errors on these morning BP surge parameters.

Simulation study 1: simulating the true lowest night SBP

Simulation study 2: the high vs. low nighttime sampling frequency on the morning BP surge parameters. The simulation was conducted by reducing the nighttime sampling frequency of ambulatory BP monitoring based on a previous published study population.⁶

Simulation study 3: simulating the true awakening time

a. Simulation study 1. Estimation of the effects of measurement errors on sleepthrough morning BP surge parameters

To estimate the influence of measurement errors on sleep-through morning BP surge parameters (the amplitude and rate of STMS), we conducted a simulation study to investigate the consequence of measurement error. The measurement error may result from the lower sampling rate at nighttime and the inaccurate oscillometric blood pressure monitoring devices. We assume that the true lowest night SBP was not captured, which is very likely to happen. Several scenarios were simulated and the STMS parameters were changed accordingly. Thus, the differences between "true" and original STMS parameters were quantified.

To demonstrate this concept, the procedures of our simulation are as followed:

- 1) Identify when the lowest night SBP is;
- 2) Simulate new lowest SBP values at different timing;
- 3) Estimate STMS rate and STMS amplitude;
- 4) Calculate the standardized mean difference.

First, we identified the observed lowest SBP at nighttime for each patient, and these observed lowest SBPs were the basis for the usage of simulation.

After the identification of the lowest SBP and its occurring time, we then quantified the influence of measurement error by exploiting the simulated "true" lowest SBP at

different timing. Given the registration frequency of night time SBP in our study is low (once per hour), the true trough could be missed. Therefore, three different values were simulated: observed lowest SBP-5, -10 and -15mm Hg as the true lowest nighttime SBP that we could not capture. Subsequently, we assumed that the true lowest SBP may have occurred before or after the original recording time. That is, the simulated true lowest SBP could either be at the time half hour earlier or later than the time we observed the lowest SBP. A total of 6 scenarios were then constructed to quantify the possible error of the observed STMS parameters. At last, to make our simulation closer to the reality, we made a randomly simulated scenario. In this scenario, we randomly simulate true lowest SBP from observed lowest SBP-5, -10, and -15 and 30 minutes before or after the original timing of lowest SBP. Then, we calculated the true "rate or amplitude" of STMS from simulated dataset obtained by the above-mentioned scenarios and compared these simulated "true" estimates with original values. The standardized mean difference (SMD) between the "simulated true value" and original estimates was calculated and compared.

From the results of SMD we noted that no matter in which scenario, STMS rate shows smaller percentage in terms of its standard deviation. To clearly show this, we've also drown plots for SMD. Thus, it is obvious that STMS rate had a smaller difference relative to its own standard deviation. Hence, we conclude that STMS rate is less sensitive to the measurement error for the night-trough SBP.

b. Simulation study 2. The influence of a lower sampling rate (one measurement per hour) was simulated by sparing regularly the nighttime BP measurements at one-hour interval, which reduced the sampling rate from twice to once per hour.

c. Simulation study 3. Influence of the inaccurate awakening time on the calculations of morning BP surge parameters was simulated by the random selection of the true awakening time at 5:00 am, 6:00 am, and 6:30 am. The morning period is defined as two hours after awakening time.

Table S1. Univariate analysis of the associations of various parameters describing night-to-morning systolic blood pressure changes **in continuous scale** with all-cause and cardiovascular mortality.

| | | All-c | ause death | | | Cardiovascular death | | | |
|------------------------------------|-------|----------|------------|----------|-------|----------------------|----------|----------|--|
| parameter | HR | 95% C.I. | 95% C.I. | p-value | HR | 95% C.I. | 95% C.I. | p-value | |
| | | (lower) | (upper) | | | (lower) | (upper) | | |
| Univariate analysis | | | | | | | | | |
| Sex (M/F 1/0) | 0.754 | 0.614 | 0.887 | 0.0006 | 0.711 | 0.529 | 0.956 | 0.0238 | |
| Age, years | 1.083 | 1.075 | 1.09 | < 0.0001 | 1.079 | 1.066 | 1.093 | < 0.0001 | |
| Height, cm | 0.984 | 0.975 | 0.993 | 0.0008 | 0.987 | 0.97 | 1.004 | 0.1265 | |
| Weight, kg | 0.991 | 0.984 | 0.999 | 0.02 | 0.997 | 0.984 | 1.01 | 0.6678 | |
| Body mass index, kg/m ² | 0.997 | 0.976 | 1.019 | 0.8104 | 1.013 | 0.974 | 1.053 | 0.5193 | |
| Alcohol, % | 1.137 | 0.902 | 1.434 | 0.2773 | 1.21 | 0.803 | 1.822 | 0.3626 | |
| Dyslipidemia, % | 1.352 | 1.106 | 1.653 | 0.0033 | 1.984 | 1.42 | 2.773 | < 0.0001 | |
| Smoking, % | 1.883 | 1.593 | 2.228 | < 0.0001 | 1.962 | 1.448 | 2.657 | < 0.0001 | |
| Hypertension, % | 1.954 | 1.663 | 2.296 | < 0.0001 | 2.273 | 1.693 | 3.051 | < 0.0001 | |
| Antihypertensive agents (%) | 1.954 | 1.663 | 2.296 | < 0.0001 | 2.273 | 1.693 | 3.051 | < 0.0001 | |
| Total cholesterol, mg/dl | 1.003 | 1 | 1.005 | 0.0189 | 1.007 | 1.003 | 1.01 | 0.0004 | |
| LDL, mg/dl | 1.002 | 0.999 | 1.004 | 0.1986 | 1.007 | 1.003 | 1.011 | 0.0005 | |
| HDL, mg/dl | 0.991 | 0.985 | 0.998 | 0.0118 | 0.983 | 0.97 | 0.996 | 0.0089 | |
| Triglycerides | 1.001 | 1 | 1.002 | 0.0025 | 1.001 | 1 | 1.002 | 0.1117 | |
| Heart rate, beats/min | 1.004 | 0.999 | 1.01 | 0.139 | 0.993 | 0.98 | 1.005 | 0.265 | |
| Office SBP, mmHg | 1.012 | 1.009 | 1.015 | < 0.0001 | 1.016 | 1.011 | 1.022 | < 0.0001 | |
| Office DBP, mmHg | 1.001 | 0.999 | 1.003 | 0.3424 | 1.002 | 1 | 1.005 | 0.1006 | |

| 24-hour SBP | 1.021 | 1.016 | 1.025 | < 0.0001 | 1.035 | 1.027 | 1.042 | < 0.0001 |
|--------------------------|-------|-------|-------|----------|-------|-------|-------|----------|
| 24-hour DBP | 1.012 | 1.005 | 1.019 | 0.0005 | 1.038 | 1.026 | 1.049 | < 0.0001 |
| Daytime SBP | 1.018 | 1.014 | 1.023 | < 0.0001 | 1.032 | 1.025 | 1.039 | < 0.0001 |
| Nighttime SBP | 1.025 | 1.021 | 1.029 | < 0.0001 | 1.037 | 1.030 | 1.044 | < 0.0001 |
| Morning SBP, mmHg | 1.019 | 1.015 | 1.023 | < 0.0001 | 1.029 | 1.022 | 1.035 | < 0.0001 |
| Amplitude of STMS, mmHg | 1.014 | 1.007 | 1.02 | < 0.0001 | 1.009 | 0.998 | 1.02 | 0.1273 |
| Rate of STMS, mmHg/hr | 1.016 | 1.01 | 1.023 | < 0.0001 | 1.017 | 1.006 | 1.029 | 0.0029 |
| Preawakening Surge, mmHg | 0.988 | 0.983 | 0.994 | < 0.0001 | 0.994 | 0.984 | 1.005 | 0.2857 |
| ME difference, mmHg | 0.99 | 0.971 | 1.01 | 0.3440 | 1.017 | 0.983 | 1.052 | 0.3286 |
| MN difference, mmHg | 0.989 | 0.981 | 0.997 | 0.0056 | 0.984 | 0.97 | 0.998 | 0.0292 |

The multivariable model was constructed with sex, age, antihypertensive treatment, body mass index, low density lipoprotein cholesterol, smoking, alcohol drinking, 24-h SBP, and the SBP night-to-day ratio. Each morning BP surge parameter was tested one-by-one by entering in the multivariable model.

Table S2. Multivariable analysis of the associations of various parameters describing night-to-morning systolic blood pressure changes **in continuous scale** with all-cause and cardiovascular mortality.

| All-cause death | | | | | Cardiovascular death | | | | |
|------------------|-------|---------------------|---------------------|---------|----------------------|---------------------|---------------------|---------|--|
| parameter | HR | 95% C.I. (lower) | 95% C.I. (upper) | p-value | HR | 95% C.I. (lower) | 95% C.I. (upper) | p-value | |
| STMS amplitude | 1.006 | 0.999 | 1.013 | 0.091 | 0.999 | 0.987 | 1.012 | 0.9224 | |
| STMS Rate | 1.023 | 1.002 | 1.044 | 0.0285 | 1.047 | 1.011 | 1.083 | 0.0093 | |
| Preawaking surge | 1.001 | 0.994 | 1.007 | 0.7881 | 1.004 | 0.992 | 1.016 | 0.4936 | |
| ME difference | 1.004 | 0.998 | 1.01 | 0.1635 | 1.003 | 0.992 | 1.013 | 0.6240 | |
| MN difference | 1.004 | 0.995 | 1.014 | 0.3545 | 1 | 0.983 | 1.017 | 0.9757 | |

The multivariable model was constructed with sex, age, antihypertensive treatment, body mass index, low density lipoprotein cholesterol, smoking, alcohol drinking, 24-h SBP, and the SBP night-to-day ratio. Each morning BP surge parameter was tested one-by-one by entering in the multivariable model.

Table S3. Sensitivity analysis by the multivariable analysis of various parameters describing night-to-morning systolic blood pressure changes using the **90th percentile** as the thresholds for predicting all-cause and cardiovascular mortality

| | | _ | Total mortality (event =607) | | Cardiovascular mortality | (event=182) | |
|-------------------------------------|-------------|-------|------------------------------|---------|--------------------------|-------------|---------|
| | *Thresholds | HR | 95%CI | P-value | HR | 95%CI | P-value |
| Amplitude of morning BP surge, mmHg | 38 | 1.072 | 0.838,1.372 | 0.58 | 0.791 | 0.484,1.294 | 0.3511 |
| Rate of morning BP surge, mmHg/hr | 8.87 | 1.415 | 1.081,1.853 | 0.01 | 1.708 | 1.085,2.688 | 0.0207 |
| Preawakening Surge, mmHg | 26.67 | 1.119 | 0.829,1.512 | 0.46 | 1.469 | 0.907,2.378 | 0.1181 |
| ME difference, mmHg | 18.67 | 1.373 | 1.084,1.739 | 0.01 | 1.381 | 0.895,2.131 | 0.1445 |
| MN difference, mmHg | 20.48 | 1.173 | 0.886,1.552 | 0.26 | 1.088 | 0.656,1.807 | 0.7436 |

^{*:} The thresholds were determined by the **90th percentile** of parameters describing the night-to-morning systolic blood pressure change These models were adjusted for sex, age, antihypertensive treatment, body mass index, low-density lipoprotein cholesterol, smoking, alcohol drinking, 24-hour systolic blood pressure, and systolic blood pressure night:day ratio.

BP = blood pressure

ME difference = difference between morning and evening systolic blood pressure

MN difference = difference between morning and night systolic blood pressure

Table S4. Sensitivity analysis by including only records with 80% successful measurements for the analysis and at least 8 BP measurements within the time interval from sleep-trough through to the morning period for multivariable Cox proportional hazard model.

| | Original data | | | | | Success rate greater than 80% | | | | |
|------------------|---------------|---------------------|---------------------|----------|-------------|-------------------------------|---------------------|----------|--|--|
| parameter | HR | 95% C.I. (lower) | 95% C.I. (upper) | p-value | HR | 95% C.I. (lower) | 95% C.I. (upper) | p-value | | |
| | | | | | | | | | | |
| STMS amplitude | 1.000521 | 0.993974 | 1.007111 | 0.876443 | 1.008833112 | 0.999074 | 1.018688 | 0.076215 | | |
| STMS Rate | 1.022821 | 1.002376 | 1.043683 | 0.028498 | 1.03255187 | 1.002137 | 1.06389 | 0.035739 | | |
| Preawaking surge | 1.001057 | 0.994519 | 1.007639 | 0.751971 | 1.003458568 | 0.993744 | 1.013268 | 0.486678 | | |
| ME difference | 1.003877 | 0.998076 | 1.009712 | 0.190686 | 1.002627091 | 0.994203 | 1.011123 | 0.542233 | | |
| MN difference | 1.004955 | 0.995507 | 1.014492 | 0.305075 | 1.008107326 | 0.994086 | 1.022327 | 0.258512 | | |

The multivariable model was constructed with sex, age, antihypertensive treatment, body mass index, low density lipoprotein cholesterol, smoking, alcohol drinking, 24-h SBP, and the SBP night-to-day ratio. Each morning BP surge parameter was tested one-by-one by entering in the multivariable model.

In addition, we also conducted the sensitivity analyses by using the 90th percentile of morning BP surge parameters as cutoff (Table S3) and by including only records with 80% successful measurements and at least 8 BP measurements within the time interval from sleep-trough through to the morning period (Table S4) for the multivariable survival analysis. The results were consistent with the original finding.

Table S5. Sensitivity analysis by multivariable analysis stratified according to subjects receiving antihypertensive agents or not: relationship with all-cause mortality

| | , | Treatment group |) | No | on-treatment gro | up | |
|------------------|----------|---------------------|---------------------|----------|---------------------|---------------------|-------------------|
| parameter | HR | 95% C.I. (lower) | 95% C.I. (upper) | HR | 95% C.I. (lower) | 95% C.I. (upper) | P for interaction |
| STMS amplitude | 1.007695 | 0.998139 | 1.017343 | 0.998205 | 0.988304 | 1.008205 | 0.7767 |
| STMS Rate | 1.010863 | 0.982672 | 1.039864 | 1.03303 | 1.003536 | 1.06339 | 0.3084 |
| Preawaking surge | 0.998634 | 0.989535 | 1.007817 | 1.002246 | 0.992933 | 1.011646 | 0.4064 |
| ME difference | 1.004571 | 0.996524 | 1.012683 | 1.003394 | 0.995053 | 1.011806 | 0.6297 |
| MN difference | 1.00466 | 0.991631 | 1.01786 | 1.004194 | 0.990333 | 1.018249 | 0.5074 |

The multivariable model was constructed with age, sex, BMI, smoking, alcohols, LDL cholesterol, 24-h SBP, and night-to-day SBP ratio. Each morning BP surge parameter was tested one-by-one by entering in the multivariable model.

Table S6. Results of Simulation studies:

| | SMD of amplitude | p-value | SMD of rate | p-value |
|-------------------------------|------------------|----------|-------------|---------|
| Simulation study 1 (N = 2015) | -0.736 | <0.0001 | -0.294 | <0.0001 |
| Simulation study 2 (N= 42) | 0.6209 | 0.0082 | 0.2973 | 0.1899 |
| Simulation study 3 (N = 2020) | | | | |
| 5:00 am vs. 6:00 am | -0.2908 | < 0.0001 | -0.1149 | 0.0103 |
| 6:30 am vs. 6:00 am | 0.1449 | 0.0012 | 0.0554 | 0.2157 |

SMD = standardized mean differences

Until now, there is no evidence of the best sampling rate for nighttime ABPM. Given the interference with sleep quality, the nighttime BP measurements with a high sampling rate probably could not faithfully reflect the real extent of nocturnal BP fall.

As shown in Table S6, the corresponding SMD in the simulation study 1 between the simulated "true" and originally observed trough values was -0.29 and -0.74 for the STMS rate and amplitude, respectively. In simulation study 2, the simulated lower sampling rate resulted in SMD 0.30 and 0.62 for rate and amplitude, respectively. If the true awakening time were before the original setting, the SMD was -0.11 and -0.29 for rate and amplitude of STMS, respectively. If the true awakening time were after the original setting, the SMD was 0.06 and 0.14 for rate and amplitude of STMS, respectively. These standardized mean differences (SMD) between the simulated and measured values was consistently lower for the STMS rate than for the STMS amplitude.

In addition, the STMS rate was less susceptible to errors than STMS amplitude when fixed circadian window was used as shown in simulation study 3.


Table S7. Reproducibility analysis based on a previous published study population 6(<u>N</u>=42)

| Parameter | Mean differences | SDD | ICC |
|------------------------|------------------|------------|------------|
| r arameter | ob1 vs ob2 | ob1 vs ob2 | ob1 vs ob2 |
| STMS amplitude, mmHg | -1.9 | 17.8 | 0.21 |
| STMS rate, mmHg/hr | 1.3 | 7.3 | 0.31 |
| Preawaking surge, mmHg | -1.4 | 21.2 | -0.10 |
| ME difference, mmHg | -3.3 | 18.9 | 0.01 |
| MN difference, mmHg | -3.1 | 19.3 | 0.13 |

Ob1: first observation measurement
Ob2: 2nd observation measurement
SDD = standard deviation of differences

ICC = intra-class correlation coefficient

Figure S1. The construction of the 6 simulated scenarios by assuming different measurement errors for the true sleep-trough systolic blood pressure (SBP) in simulation study 1.



Supplemental References:

- 1. Chen CH, Ting CT, Lin SJ, Hsu TL, Chou P, Kuo HS, Wang SP, Yin FC, Chang MS. Relation between diurnal variation of blood pressure and left ventricular mass in a chinese population. *Am J Cardiol*. 1995;75:1239-1243.
- 2. Hsu PF, Cheng HM, Wu CH, Sung SH, Chuang SY, Lakatta EG, Yin FC, Chou P, Chen CH. High short-term blood pressure variability predicts long-term cardiovascular mortality in untreated hypertensives but not in normotensives. *Am J Hypertens*. 2016;29:806-813.
- 3. Sung SH, Cheng HM, Wang KL, Yu WC, Chuang SY, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. White coat hypertension is more risky than prehypertension: Important role of arterial wave reflections. *Hypertension*. 2013;61:1346-1353.
- 4. Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. *J Hypertens*. 2011;29:454-459.
- 5. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the subcommittee of professional and public education of the american heart association council on high blood pressure research. *Circulation*. 2005;111:697-716.
- 6. Eguchi K, Hoshide S, Hoshide Y, Ishikawa S, Shimada K, Kario K. Reproducibility of ambulatory blood pressure in treated and untreated hypertensive patients. *J Hypertens*. 2010;28:918-924.
- 7. Hughes MD. Regression dilution in the proportional hazards model. *Biometrics*. 1993;49:1056-1066.